Madrigal’s MASH Breakthrough Sparks 4.83% Rally as $290M Volume Ranks 400th, Revenue Jumps 3,421%

, 2025, , ranking 400th in market activity. , . , the first EU-approved MASH treatment, . , though Cantor Fitzgerald maintained a Neutral stance.

, reinforcing investor confidence in Madrigal’s pipeline. H.C. , emphasizing market dominance in MASH therapeutics. Despite overbought technical indicators, , suggesting room for further appreciation as commercial expansion accelerates in key markets.

To build an accurate back-test, implementation details must align with specific parameters: stock universe scope (e.g., S&P 500 vs. broader U.S. equities), entry/exit timing (e.g., next-day open vs. close execution), and cost assumptions (e.g., transaction fees or slippage). Confirming these will enable precise signal generation for a portfolio test spanning January 3, 2022, to the latest market close.